ArticleCancer immunology, immunotherapy : CII2014

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.

David A Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.